The Anti CD47 Drugs Market involves therapeutic biologics targeting the CD47 receptor on cancer cells, preventing them from evading immune detection. CD47 acts as a "don't eat me" signal to macrophages and blocking it with anti-CD47 antibodies helps activate the immune system to fight cancer cells. Key products include magrolimab by Bristol Myers Squibb for hematologic cancers and ALX148 by ALX Oncology for solid tumors. The need for anti-CD47 drugs arises from their promising potential to treat various cancers resistant to conventional therapies by harnessing the immune system.
The Anti CD47 Drugs Market is estimated to be valued at US$ 0.14 Bn in 2024 and is expected to exhibit a CAGR of 42% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Anti CD47 Drugs Market are Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven. Bristol Myers Squibb's magrolimab is the most advanced anti-CD47 drug in clinical trials targeting various blood cancers.
The anti-cancer properties of CD47 inhibition and the success of initial clinical trials present lucrative opportunities for companies to expand their pipelines. Various pharmaceutical companies are conducting clinical trials across different solid tumors and hematological malignancies to tap the large market potential.
Major players are also pursuing global expansion strategies through partnerships and acquisitions. For instance, ALX Oncology licensed its lead asset ALX148 to Aspire Group in China and Forty Seven was acquired by GSK to strengthen their oncology portfolio. This is anticipated to facilitate the widespread adoption of anti-CD47 therapies globally.
Market drivers for the Anti CD47 Drugs Market include rising cancer burden worldwide driving the need for novel treatment options beyond chemotherapy and immune checkpoint inhibitors. The clinical evidence demonstrating anti-CD47 antibodies' ability to activate macrophages and induce tumor cell phagocytosis without causing anemia is also boosting their demand.
However, key restraints include challenges associated with ensuring the safety and precise targeting of anti-CD47 therapies to cancer cells alone without affecting normal cells expressing low levels of CD47.Developing truly tumor-specific anti-CD47 drugs remains an area of active research.
Segment Analysis
The Anti CD47 Drugs Market is dominated by the blood cancer sub segment. Anti CD47 drugs target the CD47 protein found on tumor cells and prevent it from sending the "don't eat me" signal to macrophages and dendritic cells. This allows the immune cells to identify and destroy cancer cells more effectively. Blood cancers like leukemia have high levels of CD47 expression making them prime targets for anti CD47 therapies. Drugs in development and clinical trials have shown promising results in treating types of leukemia, lymphoma and myeloma.
Global Analysis
The North America region holds the largest share in the Anti CD47 Drugs Market currently. This can be attributed to presence of major pharmaceutical companies investing heavily in immunotherapy research and clinical trials. The US FDA has approved several Phase I and Phase II anti CD47 drug trials for blood cancers in recent years. Asia Pacific region is expected to witness highest growth during the forecast period driven by rising healthcare investments, increasing disposable incomes and growing cancer incidence in countries like China and India. China especially is emerging as global hub for biologics manufacturing and clinical research which will support Anti CD47 Drugs Market expansion.
Get more insights on this topic: https://dailyprbulletin.com/the-rising-anti-cd47-drugs-market-is-poised-for-strong-growth-driven-by-increasing-research-and-development/
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
What Are The Key Data Covered In This Anti CD47 Drugs Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Anti CD47 Drugs 's growth between 2024 and 2031.
:- Accurate calculation of the size of the Anti CD47 Drugs and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Anti CD47 Drugs Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Anti CD47 Drugs vendors
FAQ’s
Q.1 What are the main factors influencing the Anti CD47 Drugs ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Anti CD47 Drugs companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Anti CD47 Drugs ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it